News

Novo Nordisk’s weight loss therapy linked to rare eye disorder, EU panel finds
Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say
Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...
BioSpace4d
EU Regulators Confirm Rare Vision Loss Risk for Novo’s Semaglutide
Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...
Novo Nordisk's Ozempic, Wegovy linked to rare cases of dangerous eye disorder, EMA says
The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...
Zacks Investment Research on MSN4d
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...
pharmaphorum3d
Novo Nordisk will file semaglutide for MASH next year
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
pharmaphorum4d
High-dose semaglutide ramps up weight loss, says Novo
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...